Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Director Craig A. Collard bought 2,500 shares of Opiant Pharmaceuticals stock in a transaction dated Monday, September 13th. The stock was acquired at an average cost of $18.13 per share, for a total transaction of $45,325.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ:OPNT traded up $1.85 during mid-day trading on Wednesday, reaching $21.30. The stock had a trading volume of 2,418 shares, compared to its average volume of 75,628. The firm has a market cap of $93.72 million, a PE ratio of -57.61 and a beta of 0.75. The firm has a 50 day simple moving average of $16.60 and a two-hundred day simple moving average of $13.77. The company has a current ratio of 10.46, a quick ratio of 10.46 and a debt-to-equity ratio of 0.52. Opiant Pharmaceuticals, Inc. has a twelve month low of $6.79 and a twelve month high of $19.90.
Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Thursday, August 5th. The technology company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.28) by $0.59. The firm had revenue of $11.26 million for the quarter, compared to the consensus estimate of $8.01 million. Opiant Pharmaceuticals had a negative net margin of 3.06% and a negative return on equity of 3.17%. On average, equities analysts anticipate that Opiant Pharmaceuticals, Inc. will post -0.95 EPS for the current fiscal year.
A number of brokerages recently weighed in on OPNT. TheStreet upgraded shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Wednesday, July 7th. Northland Securities began coverage on shares of Opiant Pharmaceuticals in a research report on Wednesday, July 7th. They issued a “buy” rating and a $42.00 price target on the stock.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.
Further Reading: What are the advantages to having securities held in street name?
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.